A Mother's Journey: The Birth of a Custom Medicine

When Julia Vitarello's daughter Mila was diagnosed with a rare and devastating genetic disorder, the prognosis was grim. But instead of accepting the inevitable, Vitarello fought for something no one had ever done before: a bespoke medicine designed specifically for Mila's unique disease-causing mutation. That pioneering effort, known as Milasen, saved Mila's life and sparked a new frontier in medicine. Now, eight years later, Vitarello is launching a new biotech company aimed at making such individualized therapies not just a one-off miracle, but a scalable reality.

Mila's Story: A Rare Mutation and a Bespoke Treatment

Mila suffered from a mutation in the CLN7 gene, a form of Batten disease that typically leads to severe neurological decline and early death. With no approved treatments available, Vitarello turned to researchers at Boston Children's Hospital, who created an antisense oligonucleotide (ASO) tailored to Mila's specific genetic error. The drug, named Milasen, was developed in record time and administered under a compassionate use protocol. It dramatically slowed the progression of the disease, giving Mila years of quality life. This individualized approach became a landmark case, demonstrating that precision medicine could be deployed for a single patient.

The Rise and Fall of EveryONE Medicines

Encouraged by Milasen's success, Vitarello founded EveryONE Medicines, a company with a bold mission: to create a scalable platform for producing such customized therapies for many patients, each with their own rare mutations. The concept seized the imagination of investors and patient advocates. However, the company recently folded. According to Vitarello, the primary obstacle was not technology or science, but regulation.

FDA Guidance Falls Short for Investors

In 2021, the U.S. Food and Drug Administration issued draft guidance encouraging the development of individualized therapies, including ASOs. Yet Vitarello states that the guidance did not go far enough in creating a clear, predictable regulatory pathway that would satisfy EveryONE's investors. Without a standardized approval process, the financial risk of funding dozens or hundreds of unique drugs remained too high. EveryONE could not secure the additional capital needed to continue operations, forcing it to shut down.

A New Beginning: Vitarello's Next Biotech Venture

Undeterred, Vitarello announced this week that she is in the process of starting a new biotech company. The venture will build on lessons learned from both Milasen and EveryONE Medicines, aiming to overcome the regulatory and manufacturing hurdles that stymied her previous effort. The new company, as yet unnamed, will focus on scalable production of individualized therapies, targeting a broader range of genetic mutations.

Seeking Funding and Collaborators

Vitarello and her collaborators are now actively seeking new funders—venture capital, philanthropic donors, and strategic partners. The goal is to create a hybrid model that combines academic research agility with biotech manufacturing efficiency. They plan to leverage recent advances in RNA technology and automated synthesis to reduce the cost and time of producing custom ASOs. If successful, this could democratize access to personalized medicine for thousands of patients with ultra-rare diseases that currently have no treatment options.

The Promise and Challenges of Personalized Medicine at Scale

The dream of individualized medicine at scale comes with formidable challenges. Each custom drug requires its own preclinical testing, safety assessments, and manufacturing run. Regulatory agencies must develop frameworks that ensure safety without imposing prohibitive costs. Yet the potential reward is enormous: a world where no disease is considered too rare to treat.

Technological and Regulatory Hurdles

On the technology side, improvements in sequencing, bioinformatics, and oligonucleotide chemistry are making it faster and cheaper to design and produce personalized ASOs. On the regulatory side, Vitarello and others are advocating for more flexible pathways, such as platform-based approvals where similar production methods are validated once, and only the specific sequence needs additional testing. The FDA has shown openness to such ideas, but progress is slow. The new biotech hopes to bridge this gap by demonstrating a reproducible, safe process that regulators can trust.

Vitarello's journey—from desperate mother to biotech entrepreneur—embodies the resilience needed to revolutionize medicine. Her daughter Mila continues to inspire, a living proof that even in the face of the rarest diseases, innovation can prevail. The next chapter of this story is being written now, in laboratories and boardrooms, as Vitarello works to turn one child's bespoke medicine into a hope for many.